NCT05809024招募中4 期
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker
Yongsheng Wang1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- ki67 index
研究概览
简要总结
Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Newly treated female patients, ≥18 and ≤75 years;
- •ECOG score 0-1;
- •Breast cancer following:
- •Histologically confirmed invasive breast cancer with primary tumor diameter >2 cm by standard evaluation methods.Tumor stage: cT2-cT4/cN0-cN3/cM0 (clinical phase II and III)
- •HR+/HER2- breast cancer confirmed by pathological examination, defined as: primary HR+/HER2- breast cancer performed by the pathology department of the Central Hospital;
- •Get hormone receptor status (ER and PR);
- •Major organ function following:
- •Complete blood count: Neutrophil (ANC) ≥ 1.5×109/L; Platelet count (PLT) ≥ 90×109/L; hemoglobin (Hb) ≥90 g/L; Blood Biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) ≤ 1.5×ULN; Aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Urea nitrogen (BUN) ≤ 1.5×ULN; Creatinine (Cr) ≤ 1.5×ULN; Twelve-lead electrocardiogram: Fridericia corrected QT Interval (QTcF) woman < 470 ms (QTcF=QT/(RR^1/3));
- •Woman who are not menopausal or have not been surgically sterilized agree to abstain from sex or use effective contraceptive methods for at least the duration of the study treatment and for 7 months after the last dosing;
- •Volunteer to participate in the study, sign informed consent, have good compliance and be willing to cooperate with follow-up.
排除标准
- •IV stage breast cancer or metastatic breast cancer;
- •Inflammatory breast cancer;
- •Any previous malignant tumor or previous anti-tumor therapy or radiotherapy were not allowed, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;
- •Participate in other clinical trials;
- •Patients were not allowed who had undergone major non-breast cancer related surgery within 4 weeks prior to randomization or had not fully recovered from such surgery;
- •Patients were not allowed who had received blood transfusion or colony stimulating factor treatment within 2 weeks before randomization;
- •Patients were not allowed who allergic to drug components;
- •Patients were not allowed who had a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- •Patients have heart disease were not allowed including: (1) angina pectoris; (2) medically treatable or clinically significant arrhythmias; (3) myocardial infarction; (4) heart failure; (5) any other heart disease that the investigator has determined is not suitable for participation in the study;
- •Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or fertile women who were unwilling to take effective contraceptive measures during the test period were not allowed;
- •Patients have concomitant diseases that endanger patient safety or influence the completion of the study were not allowed (including but not limited to hypertension, severe diabetes, active infection, thyroid disease, etc.);
- •Patients were not allowed who with inability to swallow, chronic diarrhea and intestinal obstruction, accompany multiple factors affecting the administration and absorption of medicines;
- •Any other circumstances in which the investigator considers the patients unsuitable for participation in the study.
研究组 & 干预措施
single Arm
Experimental
Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if ki67 was higher than 10% after two weeks,CDK4/6 Inhibitor was added.
干预措施: letrozole (Drug)
结局指标
主要结局
ki67 index
时间窗: Up to approximately 2 weeks
Independent review committee (IRC) evaluates the Ki67 index after treatment. Ki67 index using the definition of HE stained breast cancer samples after neoadjuvant therapy and surgery. (Defined by the American Joint Committee onCancer, AJCC).
次要结局
- Objective Overall Response Rate(Up to approximately 7 weeks)
研究者
Yongsheng Wang
Director of breast cancer center, Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Endocrine therapy plus CDK4/6 inhibitor in first or second line for hormone receptor positive advanced breast cancerhormone receptor positive advanced breast cancerEUCTR2017-002334-23-NLDutch Breast Cancer Research Group (BOOG)1,050
已完成
不适用
Selecteren van de optimale plaats van CDK4/6-remmer bij de behandeling van uitgezaaide hormoongevoelige (HR+) borstkanker: de SONIA studiebreast cancerNL-OMON23699BOOG study center1,050
已完成
3 期
Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trialMammary carcinoma10006291Breast cancerNL-OMON53036BOOG Study Center1,050
Unknown
1 期
Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System TumorsDigestive System TumorsNCT05139082Peking University60
招募中
不适用
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .HR+ Breast CancerNCT06734533Hunan Cancer Hospital80